- Home
- DRMA vs ATXG Comparison
DRMA vs ATXG Comparison
Compare DRMA & ATXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- ATXG
- Stock Information
- Founded
- DRMA 2014
- ATXG 2014
- Country
- DRMA United States
- ATXG China
- Employees
- DRMA N/A
- ATXG N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- ATXG Professional Services
- Sector
- DRMA Health Care
- ATXG Consumer Discretionary
- Exchange
- DRMA Nasdaq
- ATXG Nasdaq
- Market Cap
- DRMA 3.6M
- ATXG 3.8M
- IPO Year
- DRMA 2021
- ATXG N/A
- Fundamental
- Price
- DRMA $5.57
- ATXG $0.65
- Analyst Decision
- DRMA Strong Buy
- ATXG
- Analyst Count
- DRMA 1
- ATXG 0
- Target Price
- DRMA $10.00
- ATXG N/A
- AVG Volume (30 Days)
- DRMA 27.3K
- ATXG 292.7K
- Earning Date
- DRMA 08-13-2025
- ATXG 08-14-2025
- Dividend Yield
- DRMA N/A
- ATXG N/A
- EPS Growth
- DRMA N/A
- ATXG N/A
- EPS
- DRMA N/A
- ATXG N/A
- Revenue
- DRMA N/A
- ATXG $4,310,835.00
- Revenue This Year
- DRMA N/A
- ATXG N/A
- Revenue Next Year
- DRMA N/A
- ATXG N/A
- P/E Ratio
- DRMA N/A
- ATXG N/A
- Revenue Growth
- DRMA N/A
- ATXG N/A
- 52 Week Low
- DRMA $5.04
- ATXG $0.36
- 52 Week High
- DRMA $24.90
- ATXG $1.86
- Technical
- Relative Strength Index (RSI)
- DRMA 45.37
- ATXG 68.11
- Support Level
- DRMA $5.04
- ATXG $0.44
- Resistance Level
- DRMA $5.74
- ATXG $0.72
- Average True Range (ATR)
- DRMA 0.39
- ATXG 0.07
- MACD
- DRMA 0.03
- ATXG 0.02
- Stochastic Oscillator
- DRMA 48.91
- ATXG 76.92
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.